Kothari Perin
School of Medicine, Stanford University, Stanford, CA 94305, USA.
J Cardiovasc Dev Dis. 2023 Mar 2;10(3):105. doi: 10.3390/jcdd10030105.
As heart transplantation continues to be the gold-standard therapy for end-stage heart failure, the supply-demand imbalance of available organs worsens. Until recently, there have been no advances in increasing the donor pool, as prolonged cold ischemic time excludes the use of certain donors. The TransMedics Organ Care System (OCS) allows for ex-vivo normothermic perfusion, which allows for a reduction of cold ischemic time and allows for long-distance procurements. Furthermore, the OCS allows for real-time monitoring and assessment of allograft quality, which can be crucial for extended-criteria donors or donation after cardiac death (DCD) donors. Conversely, the XVIVO device allows for hypothermic perfusion to preserve allografts. Despite their limitations, these devices have the potential to alleviate the supply-demand imbalance in donor availability.
由于心脏移植仍然是终末期心力衰竭的金标准治疗方法,可用器官的供需失衡日益严重。直到最近,在增加供体库方面一直没有进展,因为延长的冷缺血时间排除了某些供体的使用。TransMedics器官护理系统(OCS)允许体外常温灌注,这可以减少冷缺血时间并实现远距离获取。此外,OCS允许对移植物质量进行实时监测和评估,这对于边缘供体或心脏死亡后捐赠(DCD)供体可能至关重要。相反,XVIVO设备允许低温灌注以保存移植物。尽管有其局限性,但这些设备有可能缓解供体可用性方面的供需失衡。